Iridoid glycosides-Kutkin, Picroside I, and Kutkoside from Picrorrhiza kurroa Benth inhibits the invasion and migration of MCF-7 breast cancer cells through the down regulation of matrix metalloproteinases. 1st Cancer Update.

Arabian Journal of Chemistry

Volumn 6, Issue 1, 2013, Pages 49-58

  Rathee, Dharmender ^a   Thanki, Madhavi ^a   Bhuva, Satish ^a   Anandjiwala, Sheetal ^a   Agrawal, Reena ^b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER AHMEDABAD   (India)

^b B V PATEL PHARMACEUTICAL EDUCATION AND RESEARCH DEVELOPMENT PERD CENTRE   (India)

Author keywords

Iridoid glycosides; Kutkin; Kutkoside; MMPs 1, 2, 9, 13; Picrorrhiza kurroa; Picroside I

Indexed keywords

IRIDOID GLYCOSIDES; KUTKIN; KUTKOSIDE; MMPS-1, 2, 9, 13; PICRORRHIZA KURROA;

CELL CULTURE; DISEASES; PROTEINS;

SUGARS;

EID: 84871696395     PISSN: 18785352     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arabjc.2011.01.011     Document Type: Article

References (61)

1. Aimes R.T., Quigley J.P. Matrix metalloproteinase-2 is an interstitial collagenase. J. Biol. Chem. 1995, 270:5872-5876.
2. Annabi B., Lachambre M.P., Bousquet-Gagnon N., Page M., Gingras D., Beliveau R. Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. Biochim. Biophys. Acta 2002, 1542:209-220.
3. Ansari R.A., Aswal B.S., Chander R., Dhawan B.N., Sharma S.K. Hepatoprotective activity of Kutkin, the iridoid glycoside mixture of Picrorrhiza kurroa. Indian J. Med. Res. 1988, 87:401-404.
4. Antarkar D.S., Vaidya A.B., Doshi J.C., Ramesh V., Kale N. A double blind clinical trial of Arogyawardhani, an Indian drug in acute viral hepatitis. Indian J. Med. Res. 1988, 72:588-593.
5. Bange J., Zwick E., Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat. Med. 2001, 7:548-552.
6. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
7. Chandler S., Miller K.M., Clements J.M., Lury J., Corkill D., Anthony D.C. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 1997, 72:155-161.
8. Colomer R., Shamon L.A., Tsai M.S., Lupu R. Herceptin: from the bench to the clinic. Cancer Invest. 2001, 19:49-56.
9. Coskun U., Yamac D., Gulbahar O., Sancak B., Karaman N., Ozkan S. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response?. Neoplasma 2007, 54:348-352.
10. De Wever O., Mareel M. Role of myofibroblasts at the invasion front. Biol. Chem. 2002, 383:55-67.
11. De Wever O., Mareel M. Role of tissue stroma in cancer cell invasion. J. Pathol. 2003, 200:429-447.
12. Decock J., Hendrickx W., Vanleeuw U., Van Belle V., Van Huffel S., Christiaens M.R., Ye S., Paridaens R. Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC Cancer 2008, 20:8-77.
13. Demeule M., Brossard M., Page M., Gingras D., Beliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochim. Biophys. Acta 2000, 1478:51-60.
14. Desmoulière A., Guyot C., Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behaviour. Int. J. Dev. Biol. 2004, 48:509-517.
15. Dollé L., Adriaenssens E., El Yazidi-Belkoura I., Le Bourhis X., Nurcombe V., Hondermarck H. Nerve growth factor receptors and signaling in breast cancer. Curr. Cancer Drug Targets 2004, 4:463-470.
16. Dredge K., Dalgleish A.G., Mariott J.B. Angiogenesis inhibitors in cancer therapy. Curr. Opin. Investig. Drugs 2003, 4:667-674.
17. Duffy M.J., Maguire T.M., Hill A., McDermott E., O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000, 2(4):252-257.
18. Eck S.M., Côté A.L., Winkelman W.D., Brinckerhoff C.E. CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells. Mol. Cancer Res. 2009, 7(7):1033-1044.
19. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
20. Farias E., Ranuncolo S., Cresta C., Specterman S., Armanasco E., Varela M., Lastiri J., Pallotta M.G., Bal De Kier J.E., Puricelli L. Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. Int. J. Cancer 2000, 89:389-394.
21. Forrbes K., Gillette K., Sehgal I. Lycopene increases urokinase receptor and fails to inhibit growth or connexin expression in a metastatically passaged prostate cancer cell line: a brief communication. Exp. Biol. Med. 2003, 228:967-971.
22. Ghisalberti E.L. Biological and pharmacological activity of naturally occurring iridoids and secoiridoids. Phytomedicine 1988, 5:147-163.
23. Guo W., Giancotti F.G. Integrin signaling during tumor progression. Nat. Rev. Mol. Cell Biol. 2004, 5:816-826.
24. Handa S.S., Sharma A., Chakraborthi K.K. Natural products and plants as liver protecting drugs. Fitoterapia 1986, 58:307-351.
25. Hauzenberger D., Bergstrom S.E., Klominek J., Sundqvist K.G. Spectrum of extracellular matrix degrading enzyme in normal and malignant T lymphocytes. Anticancer Res. 1999, 90:65-78.
26. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Nat. Cancer Inst. 2001, 93:178-193.
27. Jose Jeena K., Joy K.L., Kuttan R. Effect of Emblica officinalis, Phyllanthus amarus and Picrorrhiza kurroa on N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Lett. 1999, 136:11-16.
28. Joy K.L., Rajeshkumar N.V., Kuttan G., Kuttan R. Effect of Picrorrhiza kurroa extract on transplanted tumours and chemical carcinogenesis in mice. J. Ethnopharmacol. 2000, 71:261-266.
29. Joyce J.A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005, 7:513-520.
30. Kaegi E. Unconventional therapies for cancer: 2. Green tea. The task force on alternative therapies of the Canadian breast cancer research initiative. Can Med. Assoc. J. 1998, 158:1033-1035.
31. Kim M.S., Lee E.J., Choi H.R., Moon A. p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast cancer cells. Cancer Res. 2003, 63:5454-5461.
32. Kleiner D.E., Stetler-Stevenson W.G. Structural biochemistry and activation of matrix metalloproteinases. Curr. Opin. Cell Biol. 1993, 5:891-897.
33. Köhrmann A., Kammerer U., Kapp M., Dietl J., Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 2009, 9:188.
34. La Rocca G., Pucci-Minafra I., Marrazzo A., Taormina P., Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br. J. Cancer 2004, 90:1414-1421.
35. Langer L.G., Gupta O.P., Atal C.K. Clinical trials of Picrorrhiza kurroa as immunomodulator. Indian J. Pharmacol. 1981, 13:98-99.
36. Leppa S., Saarto T., Vehmanen L., Blomqvist C., Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin. Cancer Res. 2004, 10:1057-1063.
37. Levy A.T., Cioce V., Sobel M.E., Garbisa S., Grigioni W., Liotta L.A. Increased expression of the 72 kDa type IV collagenase in human colonic adenocarcinoma. Cancer Res. 1991, 51:439-444.
38. Liabakk N.B., Talbot I., Smith R.A., Wilkinson K., Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996, 56:190-196.
39. Librach C.L., Werb Z., Fitzgerald M.L., Chiu K., Corwin N.M., Esteves R.A. 92-kD type IV collagenase mediates invasion of human cytotrophoblasts. J. Cell Biol. 1991, 113:437-449.
40. Liotta L.A., Kohn E. The microenvironment of the tumor-host interface. Nature 2001, 430:973-974.
41. Liu S.C., Yang S.F., Yeh K.T., Yeh C.M., Chiou H.L., Lee C.Y., Chou M.C., Hsieh Y.S. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin. Chim. Acta 2006, 371:92-96.
42. Liu J.J., Huang T.S., Cheng W.F., Lu F.J. Baicalein and baicalin are potent inhibitors of angiogenesis: inhibition of endothelial cell proliferation. Int. J. Cancer 2003, 106:559-565.
43. Mittal G.C., Saxena S., Kanchan S.K., Mangal O.P., Dandiya P.C. Clinical trials on bibarin in liver disorders with special reference to infective hepatitis. Indian Pract. August 1978, 683-693.
44. Parmo-Cabanas M., Molina-Ortiz I., Matias-Roman S., Garcia-Bernal D., Carvajal-Vergara X., Valle I. Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J. Pathol. 2006, 208:108-118.
45. Pasco S., Brassart B., Ramont L., Maquart F.X., Monboisse J.C. Control of melanoma cell invasion by type IV collagen. Cancer Detect. Prev. 2005, 29:260-266.
46. Quaranta M., Daniele A., Coviello M., Venneri M.T., Abbate I., Caringella M.E., Di T.S., Divella R., Trerotoli P., Di G.M., Schittulli F., Fransvea E., Giannelli G. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res. 2007, 27:3593-3600.
47. Ranuncolo S.M., Armanasco E., Cresta C., Bal De Kier J.E., Puricelli L. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow up and in the assessment of prognosis in breast cancer patients. Int. J. Cancer 2003, 106:745-751.
48. Rathee, D., Thanki, M., Agarwal, R., Anandjiwala, S., 2011. Isolation, Characterization and Simultaneous Quantification of Picroside I and Kutkoside using HPTLC from Picrorrhiza kurroa Benth. Journal of liquid chromatography and related technologies, as accepted manuscript no.; (FILE#9079), Production tracking number: LJLC 551607.
49. Shah F.D., Shukla S.N., Shah P.M., Shukla H.K., Patel P.S. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J. Cancer 2009, 46:194-202.
50. Sheen-Chen S.M., Chen H.S., Eng H.L., Sheen C.C., Chen W.J. Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett. 2001, 173:79-82.
51. Singh G.B., Bani S., Singh S., Khajuria A., Sharma M.L., Gupta B.D., Banerjee S.K. Antiinflammatory activity of the iridoids Kutkin, Picroside-1 and Kutkoside from Picrorhiza kurroa. Phytother. Res. 1993, 7:402-407.
52. Talvensaari-Mattila A., Turpeenniemi-Hujanen T. Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett. 2005, 217:237-242.
53. Tripathi S., Mait T.K. Immunomodulatory role of native and heat denatured agglutinin from Abrus precatorius. Int. J. Biochem. Cell Biol. 2005, 37:451-462.
54. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991, 5:2145-2154.
55. Xiao T., Takagi J., Coller B.S., Wang J.H., Springer T.A. Structural basis for allostery in integrins and binding to fibrinogenmimetic therapeutics. Nature 2004, 432:59-67.
56. Yana I., Seiki M. MT-MMPs play pivotal roles in cancer dissemination. Clin. Exp. Metastasis 2002, 19:209-215.
57. Zhang B., Liu Y.X., Cao W.F., Cao X.C., Ning L.S., Hao X.S. Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer. Zhonghua Bing Li Xue Za Zhi 2008, 37:471-476.
58. Zhang M., Altuwaijri S., Yeh S. RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness. Oncogene 2004, 23:3080-3088.
59. Ziche M., Donnini S., Morbidelli L. Development of new drugs in angiogenesis. Curr. Drug Targets 2004, 5:389-406.
60. Zucker S., Lysik R.M., Zarrabi M.H., Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993, 53:140-146.
61. Zucker S., Hymowitz M., Conner C., Zarrabi HM., Hurewitz AN., Matrisian L., Boyd D., Nicolson G., Montana S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clin. Exp. Appl. Annu. N Y Acad. Sci. 1999, 878:212-227.